Timing of PSA response to guide cessation of docetaxel in prostate cancer.

被引：0
|
作者：
Dickinson, Peter D.
Malik, Jahangeer
Slevin, Finbar
Sivanandan, Ananth
Clarke, Noel W.
Choudhury, Ananya
Elliott, Tony
机构：
[1] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[2] NHS Lothian, Western Gen Hosp, Edinburgh, Midlothian, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16069
引用
收藏
页数：1
相关论文
共 50 条
  • [31] DURATION OF HORMONE SENSITIVITY AND PRE-CHEMOTHERAPY PSA ARE PREDICTORS OF RESPONSE TO DOCETAXEL IN CASTRATION-RESISTANT PROSTATE CANCER
    Spilotros, Marco
    Vavallo, Antonio
    Palumbo, Fabrizio
    Palazzo, Silvano
    Bettocchi, Carlo
    Battaglia, Michele
    Ditonno, Pasquale
    ANTICANCER RESEARCH, 2011, 31 (05) : 1892 - 1892
  • [32] Prolonged neoadjuvant endocrine therapy of prostate cancer.: PSA failure rate influenced by decreased testosterone production after cessation of endocrine therapy?
    Köllermann, J
    Caprano, J
    Budde, A
    Weidenfeld, H
    Weidenfeld, M
    JOURNAL OF UROLOGY, 2003, 169 (04): : 278 - 278
  • [33] PSA response to thalidomide in patients with advanced prostate cancer
    Leibowitz, R
    Tucker, SJ
    ONCOLOGY-NEW YORK, 2002, 16 (09): : 1146 - +
  • [34] Early prediction of therapy response to abiraterone acetate using PSA subforms in patients with castration resistant prostate cancer.
    Schlack, Katrin
    Krabbe, Laura-Maria
    Schrader, Andres Jan
    Semjonow, Axel
    Boegemann, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?
    Galego, Pedro
    Silva, Fernando C.
    Pinheiro, Luis Campos
    INTERNATIONAL BRAZ J UROL, 2015, 41 (02): : 353 - 359
  • [36] PSA surge in patients with castration-resistant prostate cancer receiving docetaxel.
    Tabata, Ken-ichi
    Satoh, Takefumi
    Matsumoto, Kazumasa
    Fujita, Tetsuo
    Iwamura, Masatsugu
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Vandetanib for treatment of hormone-resistant prostate cancer and docetaxel-resistant prostate cancer. Preclinical study
    Guerin, O.
    Etienne-Grimaldi, M.
    Fischel, J.
    Formento, P.
    Milano, G.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 5 - 5
  • [38] Immune impact induced by PSA-tricom, a therapeutic vaccine for prostate cancer.
    Madan, Ravi Amrit
    Tsang, Kwong Yok
    Jochems, Caroline
    Marte, Jennifer L.
    Tucker, Jo A.
    Hodge, James W.
    Singh, Harpreet
    Surolia, Ira
    Coyne, Geraldine Helen O'Sullivan
    Liewehr, David J.
    Steinberg, Seth M.
    Heery, Christopher Ryan
    Schlom, Jeffrey
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [39] We Need a Better Marker for Prostate Cancer. How About Renaming PSA?
    Vickers, Andrew J.
    Lilja, Hans
    UROLOGY, 2012, 79 (02) : 254 - 255
  • [40] General practitioners' reflections on using PSA for diagnosis of prostate cancer. A qualitative study
    Thorsen, Olav
    Viste, Eirik
    Lid, Torgeir Gilje
    Kjosavik, Svein R.
    SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2022, 40 (01) : 123 - 128
12345